S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients - PubMed (original) (raw)
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
Heike Hofmann et al. J Virol. 2004 Jun.
Abstract
The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia with a fatal outcome in approximately 10% of patients. SARS-CoV is not closely related to other coronaviruses but shares a similar genome organization. Entry of coronaviruses into target cells is mediated by the viral S protein. We functionally analyzed SARS-CoV S using pseudotyped lentiviral particles (pseudotypes). The SARS-CoV S protein was found to be expressed at the cell surface upon transient transfection. Coexpression of SARS-CoV S with human immunodeficiency virus-based reporter constructs yielded viruses that were infectious for a range of cell lines. Most notably, viral pseudotypes harboring SARS-CoV S infected hepatoma cell lines but not T- and B-cell lines. Infection of the hepatoma cell line Huh-7 was also observed with replication-competent SARS-CoV, indicating that hepatocytes might be targeted by SARS-CoV in vivo. Inhibition of vacuolar acidification impaired infection by SARS-CoV S-bearing pseudotypes, indicating that S-mediated entry requires low pH. Finally, infection by SARS-CoV S pseudotypes but not by vesicular stomatitis virus G pseudotypes was efficiently inhibited by a rabbit serum raised against SARS-CoV particles and by sera from SARS patients, demonstrating that SARS-CoV S is a target for neutralizing antibodies and that such antibodies are generated in SARS-CoV-infected patients. Our results show that viral pseudotyping can be employed for the analysis of SARS-CoV S function. Moreover, we provide evidence that SARS-CoV infection might not be limited to lung tissue and can be inhibited by the humoral immune response in infected patients.
Figures
FIG. 1.
Transient expression of the SARS-CoV S protein. (A) Western blot analysis of SARS-CoV S expression. 293T cells were transfected either with the empty eukaryotic expression vector pCAGGS (lane 1) or the SARS-CoV S expression constructs pcDNA3-S (lane 2) or pCAGGS-S (lane 3). After lysis in RIPA buffer, the extracts were separated by SDS-10% polyacrylamide gel electrophoresis and detected in Western blot analyses with a polyclonal rabbit serum directed against SARS-CoV particles. Numbers at left are molecular masses in kilodaltons. (B) Surface expression of SARS-CoV S protein. 293T cells were transfected with the empty expression plasmid pCAGGS or the pCAGGS-S construct. Thereafter, cells were prepared for FACS analysis and incubated with the polyclonal rabbit serum in order to detect the S protein. Results of one experiment representative of three are shown.
FIG. 2.
Tropism and infectivity of SARS-S-bearing lentiviral pseudotypes. (A) Cellular tropism of SARS-CoV S pseudotypes. SARS-CoV S-mediated infection of a panel of common cell lines was assessed. For infection, 3 ng of p24-normalized pseudotypes carrying either the pantropic VSV G as positive control, no GP (pcDNA3) as negative control, or the SARS-CoV S GP was added to the cells followed by a 2-h centrifugation at 800 × g in order to concentrate the infectious material on the cells. After 72 h, cells were lysed and luciferase activity was determined in the cell extracts. Results of a representative experiment performed in quadruplicate are shown. Comparable results were obtained in at least three different experiments with independent virus stocks. (B) Relative infectivity of pseudotypes bearing VSV G, MLV GP, and SARS-CoV S. Huh-7 cells were infected with culture supernatants containing 1 ng of viral antigen, and luciferase activity was measured 3 days after infection. Results of a representative experiment carried out in quadruplicate are shown; comparable results were obtained in an independent experiment. (C) Efficiency of transduction of Huh-7 cells with p24-normalized GFP reporter viruses. Huh-7 cells were spin infected for 2 h with 25 ng of pseudotypes bearing VSV G or SARS-CoV S or control pseudotypes lacking an envelope protein (pcDNA3). After 72 h, cells were fixed and analyzed by immunofluorescence. Results of a representative experiment carried out in quadruplicate are shown. The results were confirmed in two independent experiments.
FIG. 3.
Infection of hepatoma cells by replication-competent SARS-CoV. Huh-7 cells were mock infected (a) or infected with SARS-CoV (Frankfurt strain) (b and c) and stained with human anti SARS-CoV antiserum 24 h after infection. The cells were analyzed with a confocal laser scanning microscope (Zeiss LSM 510) at magnifications of ×10 (a and b) and ×63 (c).
FIG. 4.
Influence of inhibitors of acidification on SARS-CoV infection. Target cells were preincubated for 30 min with the indicated concentrations of ammonium chloride. Subsequently the cells were infected with pseudotypes carrying VSV G, MLV GP, or SARS-CoV S protein, which had been normalized for comparable luciferase activity upon infection of target cells in the absence of inhibitor. After 6 h, virus and inhibitor were removed from the cells, and fresh medium was added. Luciferase activity was determined in cell extracts after 72 h. The averages of three independent experiments performed in quadruplicate are shown. Error bars indicate standard errors of the means.
FIG. 5.
Neutralization of SARS-CoV S-mediated infection by polyclonal rabbit serum raised against purified SARS-CoV. Pseudotypes bearing VSV G, MLV GP, or SARS-CoV S protein, which had been normalized to equal luciferase activity upon infection of target cells in the absence of immune serum, were incubated for 30 min with the indicated dilutions of the polyclonal rabbit serum. Thereafter, the virus-antibody mixture was added to Huh-7 cells for 7 h followed by complete removal of the culture medium. Luciferase activity was determined in cell extracts after 72 h. Results of a representative experiment carried out in triplicate are shown. Similar results were obtained in two independent experiments.
FIG. 6.
Inhibition of SARS-CoV S-mediated infection by sera from SARS patients. (A) Detection of cell-surface-expressed SARS-CoV S protein by SARS patient serum. The SARS-CoV S protein was transiently expressed in 293T cells as described in the legend to Fig. 1. The cells were stained with serum from a convalescent SARS patient, and staining was analyzed by FACS. Results of a representative experiment are shown; similar results were obtained in an independent experiment. (B) Neutralization of S-bearing pseudotypes by sera from SARS patients. Pseudotypes bearing the VSV G or SARS-CoV S protein, which had been normalized to equal luciferase activity upon infection of target cells in the absence of serum, were preincubated for 30 min with serial dilutions of sera from convalescent SARS patients or control serum from a healthy donor. The virus-antibody mixture was incubated with Huh-7 cells for 7 h followed by complete removal of the culture medium. After 72 h, luciferase activity was determined in cell extracts. Each experiment was performed in triplicate; results of one out of two experiments are shown.
Similar articles
- Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein.
Giroglou T, Cinatl J Jr, Rabenau H, Drosten C, Schwalbe H, Doerr HW, von Laer D. Giroglou T, et al. J Virol. 2004 Sep;78(17):9007-15. doi: 10.1128/JVI.78.17.9007-9015.2004. J Virol. 2004. PMID: 15308697 Free PMC article. - Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.
Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, Weiss RA. Temperton NJ, et al. Emerg Infect Dis. 2005 Mar;11(3):411-6. doi: 10.3201/eid1103.040906. Emerg Infect Dis. 2005. PMID: 15757556 Free PMC article. - Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. Buchholz UJ, et al. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9. doi: 10.1073/pnas.0403492101. Epub 2004 Jun 21. Proc Natl Acad Sci U S A. 2004. PMID: 15210961 Free PMC article. - Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.
Kuhn JH, Li W, Radoshitzky SR, Choe H, Farzan M. Kuhn JH, et al. Antivir Ther. 2007;12(4 Pt B):639-50. Antivir Ther. 2007. PMID: 17944271 Review. - Cellular entry of the SARS coronavirus.
Hofmann H, Pöhlmann S. Hofmann H, et al. Trends Microbiol. 2004 Oct;12(10):466-72. doi: 10.1016/j.tim.2004.08.008. Trends Microbiol. 2004. PMID: 15381196 Free PMC article. Review.
Cited by
- Host-Virus Cophylogenetic Trajectories: Investigating Molecular Relationships between Coronaviruses and Bat Hosts.
Li W, Tahiri N. Li W, et al. Viruses. 2024 Jul 15;16(7):1133. doi: 10.3390/v16071133. Viruses. 2024. PMID: 39066295 Free PMC article. - Role of marine natural products in the development of antiviral agents against SARS-CoV-2: potential and prospects.
Nagahawatta DP, Liyanage NM, Jayawardena TU, Jayawardhana HHACK, Jeong SH, Kwon HJ, Jeon YJ. Nagahawatta DP, et al. Mar Life Sci Technol. 2024 Feb 21;6(2):280-297. doi: 10.1007/s42995-023-00215-9. eCollection 2024 May. Mar Life Sci Technol. 2024. PMID: 38827130 Review. - Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives.
Dong T, Wang M, Liu J, Ma P, Pang S, Liu W, Liu A. Dong T, et al. Chem Sci. 2023 May 3;14(23):6149-6206. doi: 10.1039/d2sc06665c. eCollection 2023 Jun 14. Chem Sci. 2023. PMID: 37325147 Free PMC article. Review. - Molecular mechanisms of human coronavirus NL63 infection and replication.
Castillo G, Mora-Díaz JC, Breuer M, Singh P, Nelli RK, Giménez-Lirola LG. Castillo G, et al. Virus Res. 2023 Apr 2;327:199078. doi: 10.1016/j.virusres.2023.199078. Epub 2023 Feb 22. Virus Res. 2023. PMID: 36813239 Free PMC article. Review. - Unspecific reactivity must be excluded in COVID-19 epidemiological analyses or virus tracing based on serologic testing: Analysis of 46,777 post-pandemic samples and 1,114 pre-pandemic samples.
Cai MJ, Lin J, Zhu JH, Dai Z, Lin YQ, Liang XM. Cai MJ, et al. Front Med (Lausanne). 2022 Nov 16;9:1018578. doi: 10.3389/fmed.2022.1018578. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36465910 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous